Product Description
Erlotinib hydrochloride is a drug used to treat non-small cell lung cancer (NSCLC), pancreatic cancer and several other types of cancer. It is a receptor tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor.
Erlotinib has shown a survival benefit in the treatment of lung cancer in phase III trials.
- Product name: Erlotinib
- CAS: 183321-74-6
- MF: C22H23N3O4
- Appearance:White powder
- Assay:99%MIN
Key Features of Erlotinib APIErlotinib API stands out for its high purity (99%) and is presented as a white powder with a long shelf life of up to 5 years. It is crafted to meet strict medicine-grade standards, making it ideal for pharmaceutical intermediates used in creating cancer therapies. As a trusted choice among exporters and suppliers in India, it offers reliability and product consistency for manufacturers.
Therapeutic ApplicationsThis API is crucial for preparing medicines that combat a range of cancers, with a strong focus on non-small cell lung cancer (NSCLC) and pancreatic cancer. Its effectiveness makes it a popular active ingredient for developing advanced cancer treatments, supporting healthcare providers in delivering innovative oncological solutions.
Safety, Handling, and StorageErlotinib API should be handled in accordance with pharmaceutical safety protocols, using appropriate personal protective equipment. Store the powder in a cool, dry place, ideally in tightly sealed containers, to maintain its efficacy and stability. Observing these guidelines ensures the API's shelf life and integrity for up to 5 years.
FAQ's of Erlotinib Api:
Q: How is Erlotinib API typically used in the pharmaceutical industry?
A: Erlotinib API is primarily utilized as a pharmaceutical intermediate in the formulation of oral cancer medicines. It is particularly effective against non-small cell lung cancer (NSCLC), pancreatic cancer, and several other malignant conditions.
Q: What are the main benefits of using high-purity Erlotinib API?
A: Using high-purity (99%) Erlotinib API ensures optimal effectiveness and safety when producing anti-cancer medications. This level of purity minimizes impurities, which can enhance drug performance and reduce potential side effects.
Q: When should Erlotinib-based medications be considered?
A: Erlotinib-based medicines are generally prescribed following a diagnosis of non-small cell lung cancer (NSCLC), pancreatic cancer, or certain other cancers, as determined by an oncologist. The suitability of Erlotinib is based on specific cancer profiles and patient health.
Q: Where can Erlotinib API be sourced from?
A: Erlotinib API can be procured from reputable exporters, suppliers, and traders in India who specialize in medicine-grade pharmaceutical intermediates. These professionals ensure compliance with quality and safety standards.
Q: What is the standard process for handling Erlotinib API in manufacturing?
A: The process involves precise weighing and blending of Erlotinib powder under controlled conditions, followed by formulation into healthcare products. Strict adherence to GMP guidelines and safety procedures is essential at every stage.
Q: How should Erlotinib API be stored to maximize its shelf life?
A: To preserve its quality and efficacy, Erlotinib API should be stored in a cool, dry area away from direct light and moisture, ideally in tightly sealed original containers. This can help maintain its stability for up to 5 years.